ATR and cancer: In recent years, NU6027, NVP-46BEZ235, Torin 2, and ETP-46464 have been reported to be more potent ATR inhibitors that have been shown to sensitize cancer cells to a variety of genotoxic chemotherapies but have also inhibited other kinases such as CDK2, PIK3, mTOR, and ATM [102].